Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Journal of Hematology & Oncology
Published in: Journal of Hematology & Oncology 1/2017

Open Access 01-12-2017 | Erratum

Erratum to: Long non-coding RNA ANRIL is upregulated in hepatocellular carcinoma and regulates cell proliferation by epigenetic silencing of KLF2

Authors: Ming-de Huang, Wen-ming Chen, Fu-zhen Qi, Rui Xia, Ming Sun, Tong-peng Xu, Li Yin, Er-bao Zhang, Wei De, Yong-qian Shu

Published in: Journal of Hematology & Oncology | Issue 1/2017

Login to get access

Excerpt

This article [1] was unintentionally published twice in this journal, by the same authors. …
Literature
1.
M-d H, W-m C, F-z Q, Xia R, Sun M, Xu T-p, Yin L, E-b Z, De W, Y-q S. Long non-coding RNA ANRIL is upregulated in hepatocellular carcinoma and regulates cell proliferation by epigenetic silencing of KLF2. J Hematol Oncol. 2015;8:57. doi:10.​1186/​s13045-015-0153-1.CrossRef
2.
M-d H, W-m C, F-z Q, Xia R, Sun M, Xu T-p, Yin L, E-b Z, De W. Shu Y-q long non-coding RNA ANRIL is upregulated in hepatocellular carcinoma and regulates cell apoptosis by epigenetic silencing of KLF2. J Hematol Oncol. 2015;8:50. doi:10.​1186/​s13045-015-0146-0.CrossRef
Metadata
Title
Erratum to: Long non-coding RNA ANRIL is upregulated in hepatocellular carcinoma and regulates cell proliferation by epigenetic silencing of KLF2
Authors
Ming-de Huang
Wen-ming Chen
Fu-zhen Qi
Rui Xia
Ming Sun
Tong-peng Xu
Li Yin
Er-bao Zhang
Wei De
Yong-qian Shu
Publication date
01-12-2017
Publisher
BioMed Central
Published in
Journal of Hematology & Oncology / Issue 1/2017
Electronic ISSN: 1756-8722
DOI
https://doi.org/10.1186/s13045-017-0513-0

Other articles of this Issue 1/2017

Journal of Hematology & Oncology 1/2017 Go to the issue

Review

Emerging therapies for acute myeloid leukemia

Review

XPO1 in B cell hematological malignancies: from recurrent somatic mutations to targeted therapy

Research

An improved pre-clinical patient-derived liquid xenograft mouse model for acute myeloid leukemia

Review

Natural compounds targeting major cell signaling pathways: a novel paradigm for osteosarcoma therapy

Research

Comparison of matched sibling donors versus unrelated donors in allogeneic stem cell transplantation for primary refractory acute myeloid leukemia: a study on behalf of the Acute Leukemia Working Party of the EBMT

Letter to the Editor

5’UTR point substitutions and N-terminal truncating mutations of ANKRD26 in acute myeloid leukemia
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits